Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Lisa Allamassey"'
Autor:
V. Ram Peddi, MD, Bradley Marder, MD, Luis Gaite, MD, Jose Oberholzer, MD, Ryan Goldberg, MD, Thomas Pearson, MD, Harold Yang, MD, PhD, Lisa Allamassey, MSc, Martin Polinsky, MD, Richard N. Formica, MD
Publikováno v:
Transplantation Direct, Vol 9, Iss 2, p e1419 (2023)
Background. Compared with calcineurin inhibitor–based immunosuppression, belatacept (BELA)-based treatment has been associated with better renal function but higher acute rejection rates. This phase 2 study (NCT02137239) compared the antirejection
Externí odkaz:
https://doaj.org/article/d9f5b687bddc42b5973f8bd8e04fbd04
Publikováno v:
Clinical Pharmacology in Drug Development
GLPG1205 is a novel agent being investigated for the treatment of idiopathic pulmonary fibrosis. GLPG1205 may be concomitantly administered with pirfenidone in future clinical development; therefore, the potential for GLPG1205 to interact with enzyme
Autor:
Flavio Vincenti, Klemens Budde, Johan W. de Fijter, M Rial, Hermann Haller, Stefan P Berger, Martin Polinsky, Lionel Rostaing, Nicolae Leca, Nassim Kamar, Avinash Agarwal, Rohini Prashar, S. Gao, Lisa Allamassey, Arjang Djamali
Publikováno v:
Journal of the American Society of Nephrology, 32(12), 3252-3264. AMER SOC NEPHROLOGY
J Am Soc Nephrol
J Am Soc Nephrol
Significance Statement This randomized trial demonstrates the safety and efficacy of conversion from calcineurin inhibitor (CNI)? to belatacept-based maintenance immunosuppression in renal transplant recipients 6?60 months post-transplant. Patients c
Autor:
Herman de Kock, D. Kanters, Florence Namour, Katja Conrath, Olivier Van de Steen, Pavel Drevinek, Edward F. McKone, Nico Derichs, Jane C. Davies, Silke van Koningsbruggen-Rietschel, Lisa Allamassey
Publikováno v:
Journal of Cystic Fibrosis. 18:693-699
Background Investigation of novel cystic fibrosis transmembrane conductance regulator (CFTR) potentiators, such as GLPG1837, for CF patients with gating mutations is challenging as trials require patients to withhold ivacaftor, the current standard o
Autor:
Toby M. Maher, Lisa Allamassey, Wim A. Wuyts, Julie Desrivot, Ellen van der Aar, Liesbeth Fagard, Ann Fieuw, S. Dupont, Olivier Van de Steen, Paul Ford
Publikováno v:
The Lancet. Respiratory medicine. 6(8)
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) causes irreversible loss of lung function. People with IPF have increased concentrations of autotaxin in lung tissue and lysophosphatidic acid (LPA) in bronchoalveolar lavage fluid and exhaled condensat